The results of clinical studies have shown that hUCMSCs are safe and well tolerated in the treatment of AS patients, with a significant decrease in bath ankylosing spondylitis disease activity index (BASDAI) and bath ankylosing spondylitis functional index (BASFI) scores (27), significant improvement in blood sedimentation, C-reactive protein (CRP), Intercellular adhesion molecule (ICAM), and TNF-α levels, and an improvement in imaging scores (8, 28–31). The gene discussed is TNF; the disease is ankylosing spondylitis.